About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.36$ per share.

The book value per share is 2.83$

Iovance Biotherapeutics, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -119M - -117M -1.36 - - 86M 2.83 -91M -1M -92M